Metabolic Syndrome (MetS)LIGHTER-MetSNCT07410325
Effectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS)
A study testing LIGHTER-MetS in people with Metabolic Syndrome (MetS) and Metabolic Syndrome, run by National University Health System, Singapore at 1 site in Singapore.
Trial summary
This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). Read more about this study
- Who is it for?
- Ages 21 to 65 years
- Conditions the study is for
- Metabolic Syndrome (MetS), Metabolic Syndrome
- What is being tested?
- LIGHTER-MetS
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 316 participants
- Where
- 1 siteSingapore
- Study dates
- 1 Jan 2026to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- are between 21 to 65 years of age;
- have a waist circumference ≥90 cm in men and ≥80 cm in women;
- have 2 or more of the following to be classified as having metabolic syndrome:
- triglyceride level of ≥1.7 mmol/L or on specific treatment for this lipid abnormality;
- high density lipoprotein (HDL) cholesterol <1.03 mmol/L in men, and <1.29 mmol/L in women, or on specific treatment for this lipid abnormality;
- blood pressure of ≥130/85 mmHg or on treatment of previously diagnosed hypertension;
Show all 10Show fewer
- fasting blood glucose level of ≥ 5.6 mmol/L or previously diagnosed type 2 diabetes;
- are not receiving other structured lifestyle modification programs;
- consent to audio-recording;
- English speaking and literate.
Who cannot join
- underwent or are scheduled for metabolic surgery within 1 year;
- are pregnant or planning for pregnancy at the time of recruitment;
- are unable to speak English;
- do not own a smartphone; and
- are unable to provide informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
National University of Singapore
Singapore, 117597
About this study
This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). The LIGHTER-MetS program, a community-based, grassroots-led initiative, integrates health coaching with the eTRIP© app to promote sustainable lifestyle changes focusing on diet, exercise, and emotion regulation.
- Conditions
- Metabolic Syndrome (MetS), Metabolic Syndrome
- Being tested
- LIGHTER-MetS
- Medical subject headings
- Metabolic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LIGHTER-MetSBehavioural
The LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan.
| Study group | Role | What they receive |
|---|---|---|
| LIGHTER-MetS | Experimental | The LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan. Receives: Behavioral: LIGHTER-MetS |
| Control | No intervention | Participants will receive personalised health plans provided as part of usual care when they see a family physician. As part of the HealthierSG initiative, health plans are typically formulated to target early disease prevention and chronic condition management through history taking, physical examination, appropriate diagnostic testing, treatment, referrals and lifestyle modification goals and activity planning. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Self regulation of Eating Behaviour Questionnaire (SREBQ)
The Self-Regulation of Eating Behaviour Questionnaire (SREBQ) is a validated self-administered instrument used to assess individuals' self-regulation in relation to eating behavior. It evaluates the extent to which individuals monitor, control, and regulate their eating behaviors in everyday contexts. Higher scores indicate greater self-regulation of eating behavior.
Measured: At baseline, 3, 6, and 12 months.
Cardiovascular Risk
Cardiovascular risk will be assessed via the ASCVD-risk calculator and the Singapore-modified Framingham Risk Score 2023 (SG-FRS-2023). Higher scores indicate a greater estimated cardiovascular risk.
Measured: At baseline, 3, 6, and 12 months.
Secondary outcomes (21)
Weight
Measured: At baseline, 3, 6, and 12 months.
Waist Circumference
Measured: At baseline, 3, 6, and 12 months.
Blood Pressure
Both systolic and diastolic blood pressure will be assessed.
Measured: At baseline, 3, 6, and 12 months.
Three Factor Eating Questionnaire (TFEQ)
The Three-Factor Eating Questionnaire (TFEQ) is a validated self-administered instrument used to assess eating-related behaviors. It measures three domains: cognitive restraint of eating, uncontrolled eating, and emotional eating. Higher scores indicate greater levels of the respective eating behavior.
Measured: At baseline, 3, 6 and 12 month.
Consideration of Future Consequences Scale (CFCS-6)
The Consideration of Future Consequences Scale - 6 item (CFCS-6) is a validated self-administered questionnaire used to assess the extent to which individuals consider the potential future outcomes of their current behaviors. It evaluates the degree to which individuals weigh immediate versus future consequences when making decisions. Higher scores indicate greater consideration of future consequences.
Measured: At baseline, 3, 6 and 12 month.
Self-Report Behavioural Automaticity Index (SRBAI)
The Self-Report Behavioural Automaticity Index (SRBAI) is a validated self-administered questionnaire used to assess the automaticity of behavior. It evaluates the extent to which a behavior is performed automatically, with little conscious thought or deliberation. Higher scores indicate greater behavioral automaticity.
Measured: At baseline, 3, 6 and 12 month.
International Physical Activity Questionnaire Short-Form (IPAQ-SF)
The International Physical Activity Questionnaire - Short Form (IPAQ-SF) is a validated self-administered questionnaire used to assess self-reported physical activity levels. It captures the frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity performed over the past 7 days.
Measured: At baseline, 3, 6 and 12 month.
Generalized Anxiety Disorder 2-item (GAD-2)
The Generalized Anxiety Disorder - 2 item (GAD-2) is a validated self-administered screening questionnaire used to assess the frequency of core anxiety symptoms over the past two weeks. Higher scores indicate greater anxiety symptom severity.
Measured: At baseline, 3, 6 and 12 month.
Patient Health Questionnaire-2 (PHQ-2)
The Patient Health Questionnaire - 2 item (PHQ-2) is a validated self-administered screening questionnaire used to assess the frequency of depressive symptoms over the past two weeks. Higher scores indicate greater depressive symptom severity.
Measured: At baseline, 3, 6 and 12 month.
Perceived Stress Scale (PSS-10)
The Perceived Stress Scale - 10 item (PSS-10) is a validated self-administered questionnaire used to assess perceived stress levels over the past month. It measures the extent to which individuals perceive situations in their lives as stressful. Higher scores indicate greater perceived stress.
Measured: At baseline, 3, 6 and 12 month.
Euro Quality of life 5 Dimensions-5 Levels (EQ-5D-5L)
The EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) is a standardized self-administered instrument used to assess health-related quality of life. It measures five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five response levels.
Measured: At baseline, 3, 6 and 12 month.
Big Five Inventory - 44 item (BFI-44)
The Big Five Inventory - 44 item (BFI-44) is a validated self-administered questionnaire used to assess personality traits across five domains: openness, conscientiousness, extraversion, agreeableness, and neuroticism. Higher scores indicate greater expression of the respective personality traits.
Measured: At baseline, 3, 6 and 12 month.
BMI
Measured using InBody 120.
Measured: At baseline, 3, 6 and 12 month.
Percentage Body Fat
Measured using InBody 120.
Measured: At baseline, 3, 6 and 12 month.
Body Fat Mass
Measured using InBody 120.
Measured: At baseline, 3, 6 and 12 month.
Visceral Fat Level
Measured using InBody 120.
Measured: At baseline, 3, 6 and 12 month.
Homeostatic Model Assessment of Insulin Resistance
Measured using (fasting blood insulin X fasting blood glucose)/22.5.
Measured: At baseline, 3 and 12 months.
Fasting Blood Glucose (mmol/L)
Fasting blood glucose is a biochemical measure of blood glucose concentration after an overnight fast, measured using standard laboratory blood analysis. Higher values indicate poorer glycaemic control.
Measured: At baseline, 3, 6 and 12 month.
Glycated haemoglobin (HbA1c) (%)
Glycated haemoglobin (HbA1c) reflects average blood glucose levels over the preceding two to three months and is measured using standard laboratory blood analysis. Higher values indicate poorer long-term glycaemic control.
Measured: At baseline, 3, 6 and 12 month.
Triglycerides (mmol/L)
Triglycerides are a lipid biomarker measured using standard laboratory blood analysis to assess circulating triglyceride levels. Higher values indicate poorer lipid profiles and increased cardiometabolic risk.
Measured: At baseline, 3, 6 and 12 month
High-density lipoprotein cholesterol (HDL-C) (mmol/L)
High-density lipoprotein cholesterol (HDL-C) is a lipid biomarker measured using standard laboratory blood analysis to assess protective cholesterol levels. Lower values indicate poorer lipid profiles and increased cardiometabolic risk.
Measured: At baseline, 3, 6 and 12 month.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start1 Jan 2026
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic Syndrome (MetS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 316 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University Health System, Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jocelyn Chew, National University Health System, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07410325
- Sponsor's protocol ID
- NUS-IRB-2024-866
- Acronym
- LIGHTER-MetS
- Status last verified
- Apr 2026
- First submitted
- 24 Jun 2025
- Last updated
- 8 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS)
- ClinicalTrials.gov ID
- NCT07410325
- Acronym / sponsor ID
- LIGHTER-MetS / NUS-IRB-2024-866
- Conditions
- Metabolic Syndrome (MetS), Metabolic Syndrome
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 316 participants (estimated)
- Lead sponsor
- National University Health System, SingaporeUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). The LIGHTER-MetS program, a community-based, grassroots-led initiative, integrates health coaching with the eTRIP© app to promote sustainable lifestyle changes focusing on diet, exercise, and emotion regulation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LIGHTER-MetS | Experimental | Behavioral: LIGHTER-MetSThe LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan. |
| Control | No intervention | –Participants will receive personalised health plans provided as part of usual care when they see a family physician. As part of the HealthierSG initiative, health plans are typically formulated to target early disease prevention and chronic condition management through history taking, physical examination, appropriate diagnostic testing, treatment, referrals and lifestyle modification goals and activity planning. |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- are between 21 to 65 years of age;
- have a waist circumference ≥90 cm in men and ≥80 cm in women;
- have 2 or more of the following to be classified as having metabolic syndrome:
- are not receiving other structured lifestyle modification programs;
- consent to audio-recording;
Key exclusion criteria (5 listed)
- underwent or are scheduled for metabolic surgery within 1 year;
- are pregnant or planning for pregnancy at the time of recruitment;
- are unable to speak English;
- do not own a smartphone; and
- are unable to provide informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LIGHTER-MetSThe LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan. | Behavioural | LIGHTER-MetS |
Primary outcome
Self regulation of Eating Behaviour Questionnaire (SREBQ)
Time frame: At baseline, 3, 6, and 12 months.
The Self-Regulation of Eating Behaviour Questionnaire (SREBQ) is a validated self-administered instrument used to assess individuals' self-regulation in relation to eating behavior. It evaluates the extent to which individuals monitor, control, and regulate their eating behaviors in everyday contexts. Higher scores indicate greater self-regulation of eating behavior.
Cardiovascular Risk
Time frame: At baseline, 3, 6, and 12 months.
Cardiovascular risk will be assessed via the ASCVD-risk calculator and the Singapore-modified Framingham Risk Score 2023 (SG-FRS-2023). Higher scores indicate a greater estimated cardiovascular risk.
21 secondary outcomes
Weight
Time frame: At baseline, 3, 6, and 12 months.
Waist Circumference
Time frame: At baseline, 3, 6, and 12 months.
Blood Pressure
Time frame: At baseline, 3, 6, and 12 months.
Three Factor Eating Questionnaire (TFEQ)
Time frame: At baseline, 3, 6 and 12 month.
Consideration of Future Consequences Scale (CFCS-6)
Time frame: At baseline, 3, 6 and 12 month.
Self-Report Behavioural Automaticity Index (SRBAI)
Time frame: At baseline, 3, 6 and 12 month.
International Physical Activity Questionnaire Short-Form (IPAQ-SF)
Time frame: At baseline, 3, 6 and 12 month.
Generalized Anxiety Disorder 2-item (GAD-2)
Time frame: At baseline, 3, 6 and 12 month.
Patient Health Questionnaire-2 (PHQ-2)
Time frame: At baseline, 3, 6 and 12 month.
Perceived Stress Scale (PSS-10)
Time frame: At baseline, 3, 6 and 12 month.
Euro Quality of life 5 Dimensions-5 Levels (EQ-5D-5L)
Time frame: At baseline, 3, 6 and 12 month.
Big Five Inventory - 44 item (BFI-44)
Time frame: At baseline, 3, 6 and 12 month.
BMI
Time frame: At baseline, 3, 6 and 12 month.
Percentage Body Fat
Time frame: At baseline, 3, 6 and 12 month.
Body Fat Mass
Time frame: At baseline, 3, 6 and 12 month.
Visceral Fat Level
Time frame: At baseline, 3, 6 and 12 month.
Homeostatic Model Assessment of Insulin Resistance
Time frame: At baseline, 3 and 12 months.
Fasting Blood Glucose (mmol/L)
Time frame: At baseline, 3, 6 and 12 month.
Glycated haemoglobin (HbA1c) (%)
Time frame: At baseline, 3, 6 and 12 month.
Triglycerides (mmol/L)
Time frame: At baseline, 3, 6 and 12 month
High-density lipoprotein cholesterol (HDL-C) (mmol/L)
Time frame: At baseline, 3, 6 and 12 month.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Metabolic Syndrome (MetS)
Recruiting
Multi-omics Dissection of Gut Microbiome Engraftment During FMT
Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC)
Recruiting
Effect of Resistance Exercises on Serum IGF-1 Levels in Knee Osteoarthritis
Osteoarthritis (Knee), Metabolic Syndrome (MetS)
Recruiting
Preoperative Oral Carbohydrate Loading and Gastrointestinal Recovery After Bariatric Surgery in Metabolic Syndrome
Metabolic Syndrome (MetS)
Recruiting
Effectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improving Insulin Resistance Among Adults With Metabolic Syndrome: A Pilot Study (PRISM-I)
Metabolic Syndrome (MetS)
Active, not recruiting
Metformin Withdrawal In Metabolic Syndrome
Metabolic Syndrome (MetS), Glucose Intolerance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LIGHTER-MetS in people with Metabolic Syndrome (MetS) and Metabolic Syndrome, run by National University Health System, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jocelyn Chew (+6565168687, dbi-lab@nus.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self regulation of Eating Behaviour Questionnaire (SREBQ) (time frame: At baseline, 3, 6, and 12 months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.